Monthly Prescribing Reference19d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
According to Vertex Pharmaceuticals, approximately 300 additional people with CF are now eligible to receive treatment.
Yahoo Finance23d
Vertex secures two FDA wins for cystic fibrosis, both with boxed warnings
Vertex Pharmaceuticals has secured two simultaneous US Food and Drug Administration (FDA) approvals for cystic fibrosis (CF) treatments, but both therapies come with boxed warnings for potential ...
AFP2d
Vertex Announces US FDA Approval of ALYFTREKâ„¢, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis
ALYFTREK is indicated for the treatment of cystic fibrosis (CF) in patients aged 6 years and older who have at least one F508del mutation or another responsive mutation in the cystic fibrosis ...
BBC4y
New cystic fibrosis drug Kaftrio on NHS is 'mind-blowing'
The Cystic Fibrosis Trust says the drug, which it described as life-saving, can be prescribed to "people aged 12 and over with two copies of the F508del mutation, or one copy of F508del and one ...
DAC/NRF2mon
Wissenswertes zu den »Caftoren«
Inzwischen sind mehr als 2000 verschiedene Mutationen bekannt, wobei bei der Mehrheit der Patienten eine F508del-Mutation vorliegt. Seit nunmehr rund zwölf Jahren gibt es mit den CFTR-Modulatoren ...
clinicaladvisor.com13d
FDA Approval Increases Eligibility for Cystic Fibrosis Medication Trikafta
An additional 94 non-F508del CFTR mutations and a boxed warning on liver injury and liver failure were included in the updated prescribing information. 1507_1515del9, 2183A→G, A1067P ...